

Article

An ortho-Iminoquinone Compound Reacts with Lysine Inhibiting Aggregation while Remodeling Mature Amyloid Fibrils.

Luiza Fernandes, Nathália Moraes, Fernanda Savacini Sagrillo, Augusto V. Magalhães, Marcela Cristina de Moraes, Luciana Romão, Jeffery W. Kelly, Debora Foguel, Neil P. Grimster, and Fernando L Palhano

ACS Chem. Neurosci., **Just Accepted Manuscript** • Publication Date (Web): 20 Apr 2017

Downloaded from <http://pubs.acs.org> on April 22, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3 1
4
5
6 2 **An *ortho*-Iminoquinone Compound Reacts with Lysine Inhibiting**
7
8 3 **Aggregation while Remodeling Mature Amyloid Fibrils.**
9
10
11 4

12
13 5 Luiza Fernandes[‡], Nathalia Moraes[‡], Fernanda S. Sagrillo[§], Augusto V. Magalhães[‡], Marcela C.
14
15 6 de Moraes[§], Luciana Romão[#], Jeffery W. Kelly[†], Debora Foguel[‡], Neil P. Grimster[†] and
16
17 7 Fernando L. Palhano^{‡,*}
18
19
20 8
21
22 9
23

24 10 [‡]Instituto de Bioquímica Médica Leopoldo de Meis, Programa de Biologia Estrutural,
25
26
27 11 Universidade Federal do Rio de Janeiro, Rio de Janeiro, 21941-590, Brazil.
28

29 12 [†]Departments of Chemistry and Molecular and Experimental Medicine and the Skaggs Institute
30
31 13 for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla,
32
33
34 14 CA 92037, USA.
35

36 15 [#]Universidade Federal do Rio de Janeiro – Pólo de Xerém, Duque de Caxias, Rio de Janeiro
37
38 16 25245-390, Brazil.
39

40
41 17 [§]Department of Organic Chemistry, Chemistry Institute, Fluminense Federal University, Niteroi,
42
43 18 Rio de Janeiro, 24020-141, Brazil.
44
45 19

1
2
3 **1 ABSTRACT**
4

5 2 Protein aggregation is a hallmark of several neurodegenerative diseases, including Alzheimer's
6
7 3 and Parkinson's diseases. It has been shown that lysine residues play a key role in the formation
8
9 4 of these aggregates. Thus the ability to disrupt aggregate formation by covalently modifying
10
11 5 lysine residues could lead to the discovery of therapeutically relevant anti-amyloidogenesis
12
13 6 compounds. Herein, we demonstrate that an *ortho*-iminoquinone (IQ) can be utilized to inhibit
14
15 7 amyloid aggregation. Using alpha-synuclein and A β_{1-40} as model systems, we observed that IQ
16
17 8 was able to react with lysine residues and reduce amyloid aggregation. We also observed that IQ
18
19 9 reacts with free amines within the amyloid fibrils preventing their dissociation and seeding
20
21
22 10 capacity.
23
24
25

26 11
27
28 12 **Keywords:** imine, amyloid aggregation, Parkinson's disease, alpha-synuclein, Alzheimer's
29
30
31 13 disease, cross-link.
32
33
34 14
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION

2 The aggregation of peptides and proteins, exacerbated by aging, is genetically and pathologically
3 linked to numerous neurodegenerative diseases, including Alzheimer's disease, Parkinson's
4 disease, as well as the systemic amyloidoses¹. As such, a wide range of normally soluble
5 intrinsically disordered peptides or folded proteins with well-defined structures can form
6 amyloid fibrils, either through mutation or environmental changes¹. These amyloid fibrils consist
7 of multiple interacting filaments, which are at least two cross- β -sheets thick. To date, a very
8 limited number of therapies exist that can slow the progression of one of the known
9 amyloidoses². Therefore, compounds capable of directly interacting with amyloidogenic proteins
10 and blocking their self-assembly, or possessing the ability to remodel mature amyloid fibrils,
11 may help in addressing this unmet medical need². Two compounds that fulfill these criteria are
12 the molecular tweezers CLR01^{3,4} and epigallocatechin-3-gallate (EGCG) (Fig S1)⁵⁻⁷. CLR01
13 binds with high affinity to lysine (Lys) residues of proteins, thereby affecting the aggregation
14 process of a broad range of amyloidogenic proteins³. The molecular mechanisms by which
15 EGCG blocks amyloid aggregation are not completely understood; however, some studies point
16 toward hydrophobic binding and Schiff base formation with Lys residues as important features
17 of the mechanism^{5,8}. Moreover, Lys residues have been shown to be important in the aggregation
18 of several amyloidogenic proteins⁹.

19 Recently, inspired by the amine oxidase enzymes¹⁰, Largeron and Fleury developed an *o*-
20 iminoquinone (IQ) compound that catalyzes the oxidation of amines to imines under mild
21 conditions¹¹ (Fig 1). To accomplish this transformation, however, it was necessary to first
22 oxidize IQ itself (step 1, Fig 1). This initial step can occur through aerobic oxidation, but with a
23 very slow rate of reaction (\sim seven days)¹¹. In contrast, the presence of metal salts, e.g., copper,

1 enhances the rate of reaction ~50 fold. The authors demonstrated that under these conditions IQ
2 was capable of oxidizing several primary amines to imines, in methanolic solutions¹¹. Due to the
3 ability of this transformation to function under polar protic conditions, we reasoned that it may
4 be possible to oxidize the Lys side-chains of proteins under aqueous conditions, thereby
5 generating imines capable of forming inter- or intra-molecular cross-links.

6 Our data show that IQ blocks the aggregation of alpha-synuclein and remodels mature amyloid
7 fibrils of alpha-synuclein and A β ₁₋₄₀ into amorphous material. The molecular mechanisms by
8 which IQ affects the aggregation of fibrils is not fully elucidated, but here we demonstrate that
9 these effects are in part dependent of presence of lysine residues within the fibrils. The data
10 presented here open several new possible avenues of investigation in the amyloid field, and the
11 mechanisms described should therefore be considered during the design of amyloid inhibitors to
12 treat these devastating diseases.

14 RESULTS AND DISCUSSION

15 To test the activity of IQ on amyloid aggregation, we first utilized the amyloidogenic protein
16 alpha-synuclein (syn) as a model system. The aggregation of syn in Lewy bodies is a typical
17 pathological hallmark of Parkinson's disease. Syn possesses fifteen lysine residues (Fig 2A).
18 Initially, we incubated monomeric syn (70 μ M) with agitation in the presence of thioflavin T
19 (ThT), a fluorogenic amyloid probe, and monitored aggregation by the increase in ThT
20 fluorescence intensity as a function of time (Fig 2B). As hypothesized, there is a dose dependent
21 reduction in the rate of syn aggregation in the presence of IQ (Fig 2B). When a ratio of 1:7 or
22 greater (syn:IQ) was used, complete inhibition of syn aggregation was observed. As a positive
23 control EGCG (Fig S1), a well-known inhibitor of syn aggregation⁶, was also studied. Here, syn

1 aggregation was completely inhibited at a ratio of 1:5 syn:EGCG, indicating that EGCG was
2 slightly more effective at preventing aggregation when compared to IQ. It is also important to
3 note that all subsequent experiments with IQ were performed in the presence of zinc (Zn^{2+}). As a
4 control, we observed no difference in the aggregation of syn monomers when incubated in the
5 presence or absence of zinc, over the time course of our experiments (Fig S3). When syn was
6 incubated with IQ at a ratio of 1:5 in the presence of 1mM zinc, we observed increased inhibitory
7 aggregation activity of IQ when compared to the absence of zinc (Fig S3). When a ratio of 1:10
8 (syn:IQ) was used, IQ efficiently blocked syn aggregation and this inhibition was not further
9 enhanced by the presence of zinc (Fig S3). In other words, zinc is important, but not essential,
10 for catalyzing the reaction between IQ and syn, especially when lower concentrations of IQ are
11 used.

12 In an effort to further characterize the effects of IQ on syn aggregation, 70 μ M syn was
13 incubated in the presence of either IQ or EGCG (1:10 - syn:compound) for 60 h. The samples
14 were then fractionated by high-speed centrifugation to yield soluble (S) and pellet (P) fractions.
15 Each fraction was subsequently treated with 8 M urea, sonicated for 30 min, boiled for 10 min
16 with SDS in order to solubilize any amyloids fibrils present¹², and resolved by SDS-PAGE (Fig
17 2C and S4). In the absence of compound, the vast majority of the syn (90%) is found in the
18 pellet, consistent with amyloid formation (Fig 2C, lanes 1 and 2; Fig S4), whereas in the
19 presence of EGCG, only soluble species with different masses (monomer, dimer, trimer, etc.)
20 were detected (Fig 2C, lanes 3 and 4; Fig S4). These cross-linked species are believed to derive
21 from Schiff base formation between the lysine of the protein and a quinone intermediate formed
22 via oxidation of EGCG⁶. In the presence of IQ (1:10 syn:IQ), approximately 80% of the syn was
23 found in the soluble fraction, thus demonstrating IQ's ability to retard aggregate formation (Fig

1
2
3 1 2C, lane 5; Fig S4). It should be noted, however, that syn was also observed in the pelleted
4
5 2 material, suggesting only partial inhibition of aggregation (Fig 2C, lane 6; Fig S4).
6
7 3 To gain further insights into the species formed during aggregation in the presence of IQ, a filter
8
9 4 retardation assay (FRA) was employed (Fig 2D). Briefly, syn was incubated for 60 h in the
10
11 5 absence or presence of IQ, and then an aliquot of each was boiled with 2% SDS and applied to a
12
13 6 membrane (0.2 μm pores), which allows the passage of soluble proteins, but traps larger
14
15 7 aggregated species. As expected, the sample incubated in the absence of IQ passed through the
16
17 8 membrane, because the aggregates formed in the incubation had been denatured through boiling
18
19 9 (Fig 2D). In contrast, when syn was incubated with IQ, part of the sample was retained in the
20
21 10 membrane. This suggests a degree of intermolecular cross-linking amongst the fibrils which
22
23 11 renders them stable to boiling with SDS (Fig 2D). It is important to note that in our FRA
24
25 12 protocol the membrane was stained with Ponceau S, the sensitivity of which is far less than some
26
27 13 other detection methods, e.g., immune detection. This may, therefore, explain why we observed
28
29 14 no retained fibrils after SDS boiling while others have observed some SDS resistant fibrils¹³. To
30
31 15 study the secondary structure of the species formed during aggregation in the presence of IQ,
32
33 16 circular dichroism (CD) was employed. In the absence of IQ, syn aggregates displayed the well
34
35 17 documented β -sheet secondary structure. In contrast, a random-coil pattern, typical of syn
36
37 18 monomers, was observed when aggregation was performed in the presence of IQ (Fig 2E).
38
39 19 Finally, the seeding capacity of fibrils formed in the presence of IQ was investigated. As has
40
41 20 been previously demonstrated, fragments of the aggregates formed in the presence of EGCG do
42
43 21 not seed the formation of other aggregates (⁶ and Fig 2F, green). In contrast, syn fibrils formed in
44
45 22 the absence of any compound do seed aggregation (Fig 2F, black). Interestingly, sonication of
46
47 23 the aggregates formed in the presence of IQ displayed reduced seeding capacity (Fig 2F -
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 compare blue with black curve). Collectively, these data suggest that IQ was able to reduce
4
5 2 amyloid aggregation of syn, resulting in soluble and insoluble species, and generating some
6
7 3 SDS-resistant aggregates with reduced seeding competence.
8
9
10 4 In order to demonstrate that the effect of IQ on syn aggregation originates from the Lys residues,
11
12 5 aggregation assays were performed in the presence and absence of free lysine (Fig 3A).
13
14 6 Interestingly, when free lysine (150:1, Lys:IQ) was added to the aggregation of syn in the
15
16 7 presence of IQ, the ability of IQ to inhibit aggregation was almost completely blocked. This
17
18 8 result suggests that, at least in part, IQ exerts its effect on syn aggregation through reaction with
19
20 9 the lysine side chains. TEM analysis of the morphology of the syn aggregates formed in the
21
22 10 absence or presence of IQ demonstrated mature fibrils when aggregation was performed in the
23
24 11 absence of IQ (Fig. 3B), while amorphous, spherical aggregates were observed in the presence of
25
26 12 IQ (1:5, Fig. 3C). Interestingly, the typical fibril architecture was restored when free Lys was
27
28 13 present (Fig. 3D). The presence of free Lys also reduced the amount of SDS-resistant aggregates
29
30 14 produced upon addition of IQ (Fig 3E).
31
32
33 15 In order to analyze whether IQ chemically modified syn, monomeric syn was incubated for 60 h
34
35 16 under aggregating conditions and subsequently analyzed by mass spectrometry (Fig 3F-I). In the
36
37 17 absence of IQ, a single peak corresponding to unmodified syn was observed (mass observed =
38
39 18 14,460 Da) (Fig 3F). However, when aggregation was performed in the presence of IQ, several
40
41 19 additional peaks were detected (Fig 3H and 3I). First, we noted the formation of oxidized syn,
42
43 20 with masses equivalent to the addition of one (+16), two (+32) or three (+48) oxygens. We also
44
45 21 observed the presence of masses corresponding to the addition of one (+164) or two (+328) IQ
46
47 22 molecules. Additional peaks for the oxidation (1-3 oxygens) of these adducts were also observed.
48
49 23 This analysis also confirmed that Zn^{2+} is important for the catalytic activity of IQ, since all peaks
50
51
52
53
54
55
56
57
58
59
60

1 related to the adduct IQ:syn were less intense in its absence (compare Fig 3H with Fig 3I). Also,
2 Zn²⁺ alone caused no changes in the primary structure of syn (compare Fig 3F with 3G).
3 Moreover, free Lys blocked the formation of the IQ:syn adduct, while the oxidation of syn was
4 still observed (data not shown). It should be noted that fully oxidized syn cannot aggregate¹⁴.
5 Taken together, these data suggest that part of IQ's ability to prevent syn aggregation is due to
6 oxidation of the monomers (Fig 1A and Fig 3A) and part to the Lys adducts formed upon
7 reaction with IQ.
8 Next, we were interested in evaluating the ability of IQ to remodel mature fibrils, as has been
9 reported for EGCG^{5,8}. To this end, mature amyloid fibrils of syn were produced (see Fig S5 for
10 fibril characterization), and subsequently incubated with IQ (1:20) or EGCG (1:20). It is
11 important to note that EGCG displaces ThT from amyloid fibrils⁵ and this explains the reduction
12 in ThT fluorescence at time point 0 (Fig 4A). This effect was not observed upon incubation with
13 IQ when fibrils of syn (Fig 4A) or fibrils of A β ₁₋₄₀ (data not shown) were used. As can be seen in
14 Fig 4A, a marked reduction in ThT fluorescence after 24 h was observed for both EGCG and IQ.
15 The remodeling activity displayed by IQ was analyzed by filter retardation assay (Fig 4B). We
16 observed that amyloid fibrils incubated in the presence of either compound became increasingly
17 resistant to SDS/boiling over time (Fig 4B). While the EGCG fibril cross-linking was faster
18 when compared with IQ (Fig 4B), we confirmed IQ's remodeling of mature amyloid fibrils by
19 electron microscopy analysis (compare Fig 4C with Fig 4D) and also their reduced seeding
20 capacity (Fig 4G). We also observed that after incubation with IQ or EGCG the syn fibrils were
21 largely no longer recognized by the conformation-dependent antibody LOC (Fig 4F), an
22 antibody raised against mature amyloid fibrils^{15,16}. Consistent with our hypothesis that IQ
23 remodels amyloid fibrils through interaction with Lys residues, we observed that IQ was

1
2
3 1 ineffective at remodeling syn fibrils when the Lys side chains were blocked by vitamin B6 or
4
5 2 acetylation (Fig 5A), or in the presence of excess of free Lys (Fig 5B,5C). We, therefore,
6
7 3 concluded that IQ was able to remodel mature amyloid fibrils of syn into SDS-resistant
8
9 4 amorphous aggregates that were also seeding incompetent.
10
11
12 5 In order to determine whether IQ was also effective at remodeling other amyloid fibrils, we
13
14 6 examined its effect on the aggregation of A β ₁₋₄₀ (Fig 6A), a peptide associated with Alzheimer's
15
16 7 disease. The A β ₁₋₄₀ peptide was agitated for 6 d at 37 °C and the resulting amyloid fibrils were
17
18 8 characterized by ThT binding (Fig S6A), transmission electron microscopy (Fig S6B), and CD
19
20 9 spectroscopy (Fig S6C). We incubated A β ₁₋₄₀ mature fibrils with IQ (1:20) for 24 h and the
21
22 10 remodeling activity was analyzed by the filter retardation assay and ThT binding. The formation
23
24 11 of SDS-resistant aggregates (Fig 6B) and the reduction in ThT fluorescence (Fig 6C) in the
25
26 12 presence of IQ demonstrate that IQ also efficiently remodels mature A β ₁₋₄₀ amyloid fibrils.
27
28 13 We next wanted to investigate whether IQ or EGCG could remodel fibrils that lack lysine
29
30 14 residues. To investigate this we used mature amyloid fibrils from islet amyloid polypeptide
31
32 15 (IAPP), which lacks both Lys and methionine residues, and was synthesized with an acetylated
33
34 16 N-terminus (Fig 7A and Fig S7)^{5,17}. When IAPP fibrils were incubated with either IQ or EGCG,
35
36 17 neither compound was able to cross-link the mature fibrils (Fig 7B), but EGCG was effective in
37
38 18 remodeling them, whereas IQ was not (Fig 7C). This result suggests that IQ activity is
39
40 19 completely dependent on the presence of free amines, and/or methionines, whereas EGCG is not.
41
42 20 The cytotoxicity of IQ was probed using human embryonic kidney cells (HEK293) (Fig S8).
43
44 21 Unlike EGCG, which was highly toxic to these cells in culture, IQ was innocuous up to 500 μ M.
45
46 22 In order to study the toxicity of IQ in a more physiologically relevant context, we cultured
47
48 23 primary murine dopaminergic neurons, the cells that degenerate in Parkinson's disease patients¹⁸.

1
2
3 1 These neuronal cells, which express the enzyme tyrosine hydroxylase, a marker for
4
5 2 dopaminergic neurons¹⁹ (Fig 8A), were incubated for 24 h with increasing concentrations of IQ
6
7
8 3 or EGCG in the presence of 100 μ M zinc. EGCG was much more toxic when compared with IQ
9
10 4 in neuronal cells (Fig 8B), as observed for HEK293 cells (Fig S8). Neuronal cells were less
11
12 5 robust than HEK cells, with the combination of IQ + zinc displaying some toxicity at 200 μ M IQ
13
14
15 6 but more pronounced at 500 μ M IQ (compare Fig 8B with S8). The reduced cellular toxicity of
16
17 7 IQ represents an important advantage of IQ over EGCG in terms of its future use as an anti-
18
19 8 amyloidogenic compound.
20
21
22 9 Finally, the specificity of IQ was probed using competition assays. We incubated monomeric syn
23
24 10 in the presence of chicken egg albumin or egg-white lysozyme and analyzed the ability of IQ to
25
26 11 inhibit syn aggregation as well as the enzymatic activity of lysozyme. For the competition
27
28 12 experiments we used an equimolar concentration of lysines per protein. We observed that the
29
30 13 presence of albumin had no effect on syn aggregation, however the presence of lysozyme
31
32 14 changed the kinetics of syn aggregation, reducing the lag time (Fig 9A). When the same
33
34 15 experiment was performed in the presence of IQ (1:10, syn:IQ), IQ completely blocked syn
35
36 16 aggregation even when albumin or lysozyme were present (Fig 9A). These data were confirmed
37
38 17 by fractionation of samples followed by SDS-PAGE (Fig 9B), where it is evident that the
39
40 18 samples incubated with albumin or lysozyme exhibit the same profile when compared to the
41
42 19 sample incubated in the absence of these proteins, even when IQ was present. In order to
43
44 20 evaluate the enzymatic activity of lysozyme after IQ treatment, syn was incubated in the
45
46 21 presence or absence of lysozyme with or without IQ (1:10, syn:IQ) for 40 h and then added to a
47
48 22 culture of *Micrococcus luteus*, a known target of lysozyme²⁰. Lysozyme hydrolyzes the beta-
49
50 23 glycosidic linkage between N-acetylmuramic acid and N-acetyl glucosamine in the
51
52
53
54
55
56
57
58
59
60

1 peptidoglycan of bacterial cell walls. Dead cells were quantified by labeling with an ethidium
2
3 homodimer probe (Fig 9C)²⁰. We observed that the activity of lysozyme was the same in the
4
5 absence or in the presence of IQ (Fig 9D, Fig S9). With these experiments we conclude that IQ
6
7 prefers syn to lysozyme, suggesting some specificity. We speculate that the preference of IQ for
8
9 syn over lysozyme can be explained by the fact that syn is an intrinsically disordered protein
10
11 (IDP) with more lysines exposed to facilitate IQ attack.
12
13 For transthyretin related amyloidoses, a regulatory agency approved drug, tafamidis, is approved
14
15 to slow disease progression. Tafamidis is a small molecule that binds with high affinity and
16
17 specificity to the folded protein transthyretin, kinetically stabilizing the tetramer and preventing
18
19 protein aggregation²¹. Tafamidis is one of the few compounds that specifically inhibits one
20
21 amyloid disease, owing to the fact that it binds to a natively folded protein. For IDPs such as syn
22
23 and A β , the development of a specific drug is more challenging². IDPs expose more of their
24
25 residues to the solvent compared to folded proteins which can be taken advantage of to achieve
26
27 selectivity.
28
29
30
31
32
33
34
35
36
37

38 CONCLUSIONS

39
40 In conclusion, we believe that IQ can efficiently block amyloid aggregation and remodel mature
41
42 amyloid fibrils. The mechanism by which IQ operates is not totally elucidated; however, the
43
44 majority of its action appears to operate through reaction with free amines (Lys) present in the
45
46 protein/peptide target. It is still unclear if the IQ effect is mediated only by protein binding (Fig 1
47
48 step 4; Fig 3H and 3I) or also involves fibril crosslinking (Fig 1, step 6; Fig 4B and Fig 5). We
49
50 are currently attempting to elucidate which of the syn lysine residues are susceptible to IQ
51
52 reaction. We believe that the findings presented in this study can be utilized as starting points for
53
54
55
56
57
58
59
60

1 medicinal chemistry efforts towards the development of compounds capable of reducing the
2 aggregation of amyloidogenic proteins or crosslinking amyloid to reduce dissociation-associated
3 proteotoxicity.

4 5 **EXPERIMENTAL METHODS**

6 ***IQ synthesis***

7 The IQ synthesis was performed as described previously, with some modifications²². Briefly, in a
8 dry 500 mL flask, polyphosphoric acid (110 g) was heated to about 50 °C. When it became less
9 sticky, acetic acid (0.46 g, 7.7 mmol) and 2-nitroresorcinol (1.00 g, 6.5 mmol) were added and
10 the mixture was stirred for 2 h at 70-80 °C. The reaction was quenched by addition of cold water
11 (300 mL) and the reaction mixture was extracted with ethyl acetate (5 x 100 mL). The combined
12 organic layers were dried over anhydrous MgSO₄ and the solvent was removed under reduced
13 pressure at 35 °C. Purification of the crude product was performed by column chromatography
14 (silica gel, hexane/EtOAc) affording the pure 1-(3-Amino-2,4-dihydroxyphenyl)-1-ethanone in
15 72 % yield (0.92 g, 4.7 mmol). This compound (1.0 g, 5.0 mmol) was poured into the
16 hydrogenation flask, followed by the addition of Pt/C (0.1 g, 10 mol %), and the mixture was
17 subjected to hydrogenation at 28 atm (420 psi) at 50 °C²³. The reaction was monitored by TLC
18 until total conversion of the starting material was achieved. The catalyst was separated by
19 filtration, and the solvent was removed under vacuum. *o*-Iminoquinone (0.8 g, 4.78 mmol, 95 %) was
20 obtained as a pale yellow solid of suitable purity for further use: mp 209-211 °C; ¹H NMR
21 (500 MHz, DMSO-d₆) δ 7.14 (d, J = 8.8 Hz, 1 H), 6.40 (d, J = 8.8 Hz, 1 H), 2.50 (s, 3 H); ¹³C
22 NMR (75 MHz, DMSO-d₆) δ 204.0, 150.8, 123.8, 120.9, 113.2, 107.5, 26.5; MS (ESI+) m/z 168
23 [M + H]⁺.

1 ***Preparation of alpha-synuclein (syn)***

2
3
4
5
6 2 Syn was purified as described previously by acidification treatment with some modifications²⁴.
7
8 3 To purify syn monomers, the lyophilized syn was resuspended in water immediately before each
9
10 4 experiment, filtered through a 0.22 μm filter and then centrifuged through a Centricon with a 100
11
12 5 kDa cut-off. The homogeneity of monomers was analyzed by analytical size-exclusion
13
14 6 chromatography performed using a SuperoseTM6 10/300 GL column equilibrated with phosphate
15
16 7 saline buffer (Fig S2A). Chromatograms were obtained by injecting samples of 10 μL at a 0.5
17
18 8 mL/min flow rate. Elution was monitored by fluorescence (Ex = 275 nm, Em = 320 nm) and
19
20 9 absorbance at 280 nm. We also used dynamic light scattering in order to characterize the purified
21
22 10 syn. Dynamic light-scattering (DLS) measurements were performed on a Brookhaven
23
24 11 Instruments Corp at 25 °C²⁵. The hydrodynamic radius of 4 nm was calculated using the
25
26 12 diffusion coefficient and the Stokes–Einstein equation (Fig S2B). The identity of syn was
27
28 13 confirmed by mass spectrometry. The mature syn amyloid fibrils were obtained by incubation of
29
30 14 monomeric syn (140 μM) in phosphate saline buffer (PBS) pH 7.4 with 0.02% NaN_3 with
31
32 15 agitation (rotation at 24 rpm) at 25 °C for 6 d.
33
34
35
36
37
38

39 ***Preparation of A β ₁₋₄₀***

40
41
42 17 A β ₁₋₄₀ fibrils were prepared as previously described¹². A β ₁₋₄₀ was synthesized using a standard
43
44 18 Fmoc chemistry strategy for solid phase peptide synthesis. The resulting peptide was purified by
45
46 19 reversed phase C18 high-performance liquid chromatography (RP-HPLC) and characterized by
47
48 20 matrix-assisted laser desorption ionization mass spectrometry using sinapinic acid as a matrix
49
50 21 and nanostructure initiator mass spectrometry (NIMS)-TOF analysis was performed using a
51
52 22 VoyagerDE STR TOF (Applied Biosystems, Foster City, CA) mass spectrometer in reflectron
53
54
55
56
57
58
59
60

1 mode. The fibrils were produced after 6 d aggregation at 37 °C in 50 mM phosphate buffer pH
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 mode. The fibrils were produced after 6 d aggregation at 37 °C in 50 mM phosphate buffer pH
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

3 ***Preparation of Islet Amyloid Polypeptide (IAPP)***

4 IAPP_{Ac8-37} was synthesized with an acetylated N-terminus (Ac) by GenScript. The purity was
5 greater than 95% as analyzed by RP-HPLC and the correct mass was confirmed by electrospray
6 ionization (ESI). Peptide stock solutions were prepared by dissolving a weighed amount of
7 peptide in 8 M guanidine HCl, 50 mM phosphate buffer pH 7.4 to obtain a final concentration of
8 20 mg/ml. The peptides were sonicated for 1 h and centrifuged (10 min at 16,000 g at 25 °C) to
9 remove insoluble material. The concentration of the stock solutions was determined by Bradford
10 assay. The peptide stock solutions were diluted (~80 fold) in 50 mM phosphate buffer pH 7.4,
11 150 mM NaCl and 0.02% NaN₃ to a final concentration of 0.25 mg/ml and 0.1 M guanidine HCl.
12 The samples were incubated with agitation (rotation at 24 rpm) at 25 °C for 6 d. The fibrils were
13 centrifuged (16,000 g for 10 min at 4 °C), the supernatant was removed and the pellet was stored
14 at -20 °C until use.

15 ***EGCG and IQ preparation***

16 EGCG (Fig S1) obtained from Sigma-Aldrich was prepared in fresh ultra-pure water and aliquots
17 of the stock solution (5 mM) were stored at -20 °C until use. Ten milligrams of IQ was dissolved
18 in 100% DMSO to a final concentration of 300 mM. The stock solution was diluted in ultra pure
19 water to a final concentration of 5 mM and stored protected from light at -20 °C until use.

20 ***Thioflavin T (ThT) assay***

1
2
3 1 For kinetics experiments, the samples containing ThT (10 μ M) were incubated at 37 $^{\circ}$ C in a 96-
4
5
6 2 well plate (Costar # 3631) together with Teflon spheres, 0.3 cm diameter. Every 5 min, the plates
7
8 3 were shaken for 30 s, and fluorescence (excitation at 450 nm, emission at 477 nm) was
9
10 4 monitored using a SpectraMax Paradigm Multi-Mode Microplate Reader. For steady state ThT
11
12 5 binding assays, the samples were diluted to 5 μ M in PBS pH 7.4 containing 20 μ M ThT and
13
14
15 6 incubated at 25 $^{\circ}$ C for 0.5 h. Binding was monitored using a spectrofluorimeter to measure the
16
17 7 fluorescence increase (excitation at 450 nm and fluorescence emission at 470-520 nm) at 25 $^{\circ}$ C.
18
19

20 21 8 ***Filter retardation (FR) assay***

22
23
24 9 The samples were incubated in the presence of 2% SDS and boiled or not for 10 min, then
25
26 10 applied to a nitrocellulose membrane using a DOT blot apparatus under vacuum²⁶. For the FR
27
28 11 assay, the samples were stained using Ponceau.
29
30

31 32 12 ***Circular dichroism***

33
34
35 13 Circular dichroism (CD) measurements were performed in a Jasco spectropolarimeter using a
36
37 14 0.01 mm path-length quartz cuvette. The buffer used for CD measurements was phosphate saline
38
39 15 buffer, pH 7.4. Data were averaged for three scans at a speed of 100 nm/min collected in 0.2 nm
40
41 16 steps at 25 $^{\circ}$ C. The baseline (buffer alone) was subtracted from the corresponding spectra.
42
43
44

45 17 ***Fractionation of aggregates***

46
47
48 18 The samples were fractioned through high-speed centrifugation (16,000 g for 30 min, 15 $^{\circ}$ C) to
49
50 19 yield a soluble and a pellet fraction and then each fraction was treated with 8 M urea, sonicated
51
52 20 for 30 min and boiled for 10 min with 2% SDS in order to solubilize any amyloids fibrils
53
54
55 21 present.
56
57
58
59
60

1 *Mass spectrometry*

2 The samples were diluted to 7.5 μM in 3% acetonitrile and 0.1% formic acid and loaded onto a
3 Waters Nano Acquity system (Waters, Milford, MA). The sample injection volume was 2.0 μl .
4 Proteins were desalted using a trap column (Waters Symmetry C18 180 μm X 20 mm, 5 μm) and
5 the LC was performed with a linear gradient (0–60%) of acetonitrile containing 0.1% formic acid
6 at a 1.0 $\mu\text{L}/\text{min}$ flow. Electrospray tandem mass spectra were recorded using a Q-ToF
7 quadrupole/orthogonal acceleration time-of-flight spectrometer (Waters, Milford, MA)
8 interfaced to the Nano Acquity system capillary chromatograph. The ESI voltage was set at
9 3500 V, the source temperature was 80 $^{\circ}\text{C}$, and the cone voltage was 30 V. The instrument
10 control and data acquisition were conducted by a MassLynx data system (Version 4.1, Waters),
11 and experiments were performed by scanning from a mass-to-charge ratio (m/z) of 50–2000
12 using a scan time of 1 s, applied during the whole chromatographic process. All data were
13 processed manually in MassLynx and the average molecular weight was determined through
14 charge state deconvolution using the Maximum entropy Algorithm (MaxEnt 1, Waters, Milford,
15 MA).

16 *Seeding Experiments.*

17 A monomeric solution of protein (syn = 70 μM) was incubated in the absence or presence of 5%
18 seeds in phosphate saline buffer pH 7.4 with agitation. The seeds were produced by 30 min
19 sonication. The samples containing ThT (10 μM) were incubated at 37 $^{\circ}\text{C}$ in a 96-well plate, and
20 every 5 min the fluorescence (excitation at 450 nm, emission at 477 nm) was monitored.

21 *MTT Metabolic Assay.*

1
2
3 1 Primary cultures of dopaminergic neurons were prepared from the mesencephalon of 14-day-old
4
5 2 Swiss Mice embryos (E14), as previously described²⁷. Pregnant Swiss mice were anesthetized
6
7 3 and decapitated; the brain structures of the 14-day-old embryos were removed and dissociated
8
9
10 4 cells were plated on coverslips treated with poly-L-ornithine (1.5 mg/ml; Sigma-Aldrich) in
11
12 5 serum-free neurobasal medium. The cultures were incubated at 37 °C in a humidified 5% CO₂
13
14 6 and 95% air chamber for 7 days. These neuronal cell cultures were assayed by
15
16
17 7 immunocytochemistry with anti-tyrosine hydroxylase (1:100; Millipore) antibody and anti-
18
19 8 MAP2 (1:100; Millipore). The cells were incubated with increasing concentrations of IQ or
20
21 9 EGCG in the presence of 0.1 M zinc sulfate for 24 h. HEK293 cells were cultured in DMEM
22
23 10 medium supplemented with 10% FBS, 100 U/mL gentamicin in a 5% CO₂ humidified
24
25
26 11 environment at 37 °C. Cells were plated at a density of 10,000 cells/well on 96-well plates in 100
27
28 12 μL of fresh medium. After 24 h, the compounds were added, and the cells were incubated for 2 d
29
30 13 at 37 °C. Cytotoxicity was measured utilizing the 3-(4,5-dimethylthiazolyl)-2,5-
31
32
33 14 diphenyltetrazolium bromide (MTT) assay. Absorbance values of formazan were determined at
34
35 15 570 nm after 0.5 h of incubation.
36
37

38 ***Electron Microscopy***

39
40
41 17 Copper grids (carbon- and formvar-coated 400 mesh) (Electron Microscopy Sciences, Hatfield
42
43 18 PA) were glow discharged and 2 μL of sample was applied for 3 min. Excess sample was
44
45 19 removed and the grids immediately incubated with 2 % uranyl acetate solution for 2 min. Excess
46
47 20 stain was removed and the grid allowed to dry thoroughly. Grids were then examined on a
48
49 21 Tecnai Spirit (FEI Company) microscopy at 120 kV.
50
51
52

53 ***Chemical blocking of lysines of amyloid fibrils.***

1
2
3 1 Syn amyloid fibrils (120 μ M) in 20 mM borate buffer pH 8.0 were incubated with 10 mM acetic
4
5 2 anhydride overnight at 25 $^{\circ}$ C. The acetylated fibrils were dialyzed overnight against phosphate
6
7 3 buffer pH 7.4. For pyridoxal 5'-phosphate (PLP) modification, syn amyloid fibrils (120 μ M) in
8
9 4 20 mM borate buffer were incubated with 10 mM PLP for 2 h, then 20 mM sodium borohydride
10
11 5 was added for 1 h at 25 $^{\circ}$ C. The PLP-modified fibrils were dialyzed overnight against phosphate
12
13 6 buffer pH 7.4. All reactions were performed protected from light.
14
15
16
17

18 ***Dot blot***

19
20
21 8 LOC antibody was raised against mature amyloid fibrils derived from islet amyloid polypeptide.
22
23 9 This antibody can distinguish between amyloid fibrils and oligomeric and monomeric species¹⁵.
24
25 10 The samples were spotted (2 μ l) onto a nitrocellulose membrane. The membrane was blocked
26
27 11 using 1 vol PBS + 1 vol blocking solution (Odyssey) for 1 h. The membrane was incubated with
28
29 12 LOC antibody (1:1,000, Millipore) or syn-1 antibody (1:1,000, Sigma) (diluted in 1 vol TBST
30
31 13 (50 mM Tris pH 7.6, 0.9% NaCl, 0.1% Tween 20) +1 vol blocking solution for 1 h, washed 3
32
33 14 times with TBST and then incubated for 1 h with goat anti-rabbit secondary antibody conjugated
34
35 15 to IRDye 800 CW (1:5,000) for LOC or goat anti-mouse secondary antibody conjugated to
36
37 16 IRDye 680 CW (1:5,000) for syn-1 and developed/quantified using an Odyssey Infrared Imaging
38
39 17 System.
40
41
42
43
44

45 ***Competition assay with lysozyme and albumin***

46
47
48 19 Monomeric syn (70 μ M) was incubated in the absence or in the presence of 52 μ M chicken egg
49
50 20 albumin (Uniprot ID: P01012, Sigma) or 175 μ M egg-white lysozyme (Uniprot ID: P00698,
51
52 21 Sigma) in order to have equimolar concentration of lysines for each protein (1 mM). The samples
53
54 22 were incubated at 37 $^{\circ}$ C in PBS in the absence or in the presence of 700 μ M IQ + 1 mM ZnSO₄,
55
56
57
58
59
60

1 as described in the “Thioflavin T (ThT) assay”. After 40 h aggregation, an aliquot of the samples
2 was processed as described in the “Fractionation of aggregates”. To assess the enzymatic activity
3 of lysozyme, we modified the previous method described by Shugar²⁸. *Micrococcus luteus* was
4 grown overnight on Supplemented Tryptic Soy Broth (TSB) under aerobic conditions (200 rpm,
5 37 °C). The bacteria was centrifuged at 16,000 g 10 °C for 10 min, resuspended in 0.1M
6 potassium phosphate buffer pH 7.0 to give an OD_{450nm}=2.0 and stored at 4 °C. One µl of each
7 sample (syn, syn+IQ, syn+lysozyme or syn+lysozyme+IQ) was incubated with 5 µl cells for 1 h
8 at 25 °C. One micromolar ethidium homodimer (Thermo Fisher) was added and the cells were
9 analyzed in EVOS Cell Imaging Fluorescence Microscopy under 40 X objective.

10 ***Data Processing***

11 The error bars represent the S.D. of three independent measurements. For all experiments, the
12 graphics or images presented are representative of three independent experiments.

14 **ASSOCIATED CONTENT**

15 **Supporting Information**

16 Additional figures S1 to S9. This material is available free of charge via the Internet at
17 <http://pubs.acs.org>.

19 **AUTHOR INFORMATION**

20 Corresponding Author

21 palhano@bioqmed.ufrj.br

1 1 **AUTHOR CONTRIBUTIONS**

2 2 FLP and NPG conceived and coordinated the study. LF, NPG, JWK, DF and FLP wrote the
3 3 paper. LF, NM and FLP designed, performed and analyzed all experiments. NPG, NM, FSS and
4 4 MCM were responsible by the synthesis and characterization of *ortho*-iminoquinone. LR
5 5 provided assistance and contributed to the experiments with dopaminergic cells. AVM was
6 6 responsible for mass spectrometry experiments and analyses.
7
8
9

10 8 **FUNDING SOURCES**

11 9 This work was supported by grants from the Conselho Nacional de Desenvolvimento Científico
12 10 e Tecnológico (CNPq), the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do
13 11 Rio de Janeiro (FAPERJ) and the Coordenação de Aperfeiçoamento de Pessoal de Nível
14 12 Superior (CAPES).
15
16
17
18

19 14 **CONFLICT OF INTEREST**

20 15 The authors declare no conflict of interest.
21
22
23
24
25

26 17 **ACKNOWLEDGMENT**

27 18 We thank Satiago Alonso and Ana Lucia O. Carvalho for technical assistance. We also thank Dr
28 19 Colleen Fearn for critical reading of the manuscript. We thank Dra Rossolina Zingali for the use
29 20 of her laboratory facilities. We thank Dr Marco Antônio Miguel for providing the *Micrococcus*
30 21 *luteus* strain.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 REFERENCES**
4
5

- 6 2 (1) Chiti, F., and Dobson, C. M. (2006) Protein misfolding, functional amyloid, and human
7 disease. *Annu. Rev. Biochem.* 75, 333–366.
8
9 3
10
11 4 (2) Eisele, Y. S., Monteiro, C., Fearn, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., and
12 Kelly, J. W. (2015) Targeting protein aggregation for the treatment of degenerative diseases. *Nat*
13 *Rev Drug Discov* 14, 759–780.
14
15 6
16
17 7 (3) Sinha, S., Lopes, D. H. J., Du, Z., Pang, E. S., Shanmugam, A., Lomakin, A., Talbiersky, P.,
18 Tennstaedt, A., McDaniel, K., Bakshi, R., Kuo, P.-Y., Ehrmann, M., Benedek, G. B., Loo, J. A.,
19 Klärner, F.-G., Schrader, T., Wang, C., and Bitan, G. (2011) Lysine-Specific Molecular
20 Tweezers Are Broad-Spectrum Inhibitors of Assembly and Toxicity of Amyloid Proteins. *J. Am.*
21 *Chem. Soc.* 133, 16958–16969.
22
23 9
24
25 10
26
27 11
28
29 12 (4) Lump, E., Castellano, L. M., Meier, C., Seeliger, J., Erwin, N., Sperlich, B., Stürzel, C. M.,
30 Usmani, S., Hammond, R. M., Einem, von, J., Gerold, G., Kreppel, F., Bravo-Rodriguez, K.,
31 Pietschmann, T., Holmes, V. M., Palesch, D., Zirafi, O., Weissman, D., Sowislok, A., Wettig, B.,
32 Heid, C., Kirchhoff, F., Weil, T., Klärner, F.-G., Schrader, T., Bitan, G., Sanchez-Garcia, E.,
33 Winter, R., Shorter, J., and Münch, J. (2015) A molecular tweezer antagonizes seminal amyloids
34 and HIV infection. *eLife* 4, 10727.
35
36 15
37
38 16 (5) Palhano, F. L., Lee, J., Grimster, N. P., and Kelly, J. W. (2013) Toward the Molecular
39 Mechanism(s) by Which EGCG Treatment Remodels Mature Amyloid Fibrils. *J. Am. Chem.*
40 *Soc.* 135, 7503–7510.
41
42
43 18 (6) Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann,
44 S., Pastore, A., and Wanker, E. E. (2008) EGCG redirects amyloidogenic polypeptides into
45 unstructured, off-pathway oligomers. *Nat. Struct. Mol. Biol* 15, 558–566.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 1 (7) Ehrnhoefer, D. E., Duennwald, M., Markovic, P., Wacker, J. L., Engemann, S., Roark, M.,
4
5 2 Legleiter, J., Marsh, J. L., Thompson, L. M., Lindquist, S., Muchowski, P. J., and Wanker, E. E.
6
7 3 (2006) Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and
8
9 4 reduces toxicity in Huntington's disease models. *Hum. Mol. Gen* 15, 2743–2751.
- 11
12 5 (8) Bieschke, J., Russ, J., Friedrich, R. P., Ehrnhoefer, D. E., Wobst, H., Neugebauer, K., and
13
14 6 Wanker, E. E. (2010) EGCG remodels mature α -synuclein and amyloid- fibrils and reduces
15
16 7 cellular toxicity. *Proc Natl Acad Sci USA* 107, 7710–7715.
- 18
19 8 (9) Sinha, S., Lopes, D. H. J., and Bitan, G. (2012) A Key Role for Lysine Residues in Amyloid
20
21 9 β -Protein Folding, Assembly, and Toxicity. *ACS Chem. Neurosci.* 3, 473–481.
- 23
24 10 (10) Finney, J., Moon, H.-J., Ronnebaum, T., Lantz, M., and Mure, M. (2014) Archives of
25
26 11 Biochemistry and Biophysics. *Arch. Biochem. Biophys.* 546, 19–32.
- 28
29 12 (11) Largeron, M., and Fleury, M.-B. (2012) A Biologically Inspired Cu I/Topaquinone-Like Co-
30
31 13 Catalytic System for the Highly Atom-Economical Aerobic Oxidation of Primary Amines to
32
33 14 Imines. *Angew. Chem. Int. Ed.* 51, 5409–5412.
- 35
36 15 (12) Murray, A. N., Palhano, F. L., Bieschke, J., and Kelly, J. W. (2013) Surface adsorption
37
38 16 considerations when working with amyloid fibrils in multiwell plates and Eppendorf tubes.
39
40 17 *Protein Sci.* 22, 1531–1541.
- 42
43 18 (13) Lam, H. T., Graber, M. C., Gentry, K. A., and Bieschke, J. (2016) Stabilization of α -
44
45 19 Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity.
46
47 20 *Biochemistry* 55, 675–685.
- 49
50 21 (14) Hokenson, M. J., Uversky, V. N., Goers, J., Yamin, G., Munishkina, L. A., and Fink, A. L.
51
52 22 (2004) Role of individual methionines in the fibrillation of methionine-oxidized α -synuclein.
53
54 23 *Biochemistry* 43, 4621–4633.

- 1
2
3 1 (15) Kayed, R., Head, E., Sarsoza, F., Saing, T., Cotman, C. W., Necula, M., Margol, L., Wu, J.,
4
5 2 Breydo, L., Thompson, J. L., Rasool, S., Gurlo, T., Butler, P., and Glabe, C. G. (2007) Fibril
6
7 3 specific, conformation dependent antibodies recognize a generic epitope common to amyloid
8
9 4 fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol Neurodegener.* 2, 18.
10
11 5 (16) Greiner, E. R., Kelly, J. W., and Palhano, F. L. (2014) Immunoprecipitation of Amyloid
12
13 6 Fibrils by the Use of an Antibody that Recognizes a Generic Epitope Common to Amyloid
14
15 7 Fibrils. *PLoS ONE* 9, e105433.
16
17 8 (17) Cao, P., and Raleigh, D. P. (2012) Analysis of the Inhibition and Remodeling of Islet
18
19 9 Amyloid Polypeptide Amyloid Fibers by Flavanols. *Biochemistry* 51, 2670–2683.
20
21 10 (18) Rodrigues, T. M., Jerónimo-Santos, A., Outeiro, T. F., Sebastião, A. M., and Diógenes, M.
22
23 11 J. (2014) Challenges and promises in the development of neurotrophic factor-based therapies for
24
25 12 Parkinson's disease. *Drugs Aging* 31, 239–261.
26
27 13 (19) St Martin, J. L., Klucken, J., Outeiro, T. F., Nguyen, P., Keller-McGandy, C., Cantuti-
28
29 14 Castelvetri, I., Grammatopoulos, T. N., Standaert, D. G., Hyman, B. T., and McLean, P. J.
30
31 15 (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by
32
33 16 targeted over-expression of alpha-synuclein in mouse substantia nigra. *J. Neurochem.* 100,
34
35 17 1449–1457.
36
37 18 (20) Dutta, P., Ray, N., Roy, S., Dasgupta, A. K., Bouloussa, O., and Sarkar, A. (2011) Covalent
38
39 19 immobilization of active lysozyme on Si/glass surface using alkoxy Fischer carbene complex on
40
41 20 SAM. *Org. Biomol. Chem.* 9, 5123–5128.
42
43 21 (21) Bulawa, C. E., Connelly, S., Devit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J.,
44
45 22 Powers, E. T., Wiseman, R. L., Foss, T. R., Wilson, I. A., Kelly, J. W., and Labaudiniere, R.
46
47 23 (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 cascade. *Proc Natl Acad Sci USA* 109, 9629–9634.
- 2
- 3 1 cascade. *Proc Natl Acad Sci USA* 109, 9629–9634.
- 4
- 5 2 (22) Xu, D., Chiaroni, A., Fleury, M.-B., and Langeron, M. (2006) Electrochemically induced
- 6
- 7 3 cascade reaction for the assembly of libraries of biologically relevant 1,4-benzoxazine
- 8
- 9 4 derivatives. *J. Org. Chem.* 71, 6374–6381.
- 10
- 11
- 12 5 (23) Facchinetti, V., Guimarães, F. A., Souza, M. V. N., Gomes, C. R. B., Souza, M. C. B. V.,
- 13
- 14 6 Wardell, J. L., Wardell, S. M. S. V., and Vasconcelos, T. R. A. (2015) Synthesis of Novel Ethyl
- 15
- 16 7 (substituted)phenyl-4-oxothiazolidin-3-yl-1-ethyl-4-oxo-1,4-dihydroquinoline-3-
- 17
- 18 8 Carboxylates as Potential Anticancer Agents. *J. Heterocyclic Chem.* 52, 1245–1252.
- 19
- 20
- 21 9 (24) Coelho-Cerqueira, E., Carmo-Gonçalves, P., Pinheiro, A. S., Cortines, J., and Follmer, C.
- 22
- 23 10 (2013) α -Synuclein as an intrinsically disordered monomer--fact or artefact? *FEBS J.* 280, 4915–
- 24
- 25 11 4927.
- 26
- 27
- 28 12 (25) Dusa, A., Kaylor, J., Edridge, S., Bodner, N., Hong, D.-P., and Fink, A. L. (2006)
- 29
- 30 13 Characterization of Oligomers during α -Synuclein Aggregation Using Intrinsic Tryptophan
- 31
- 32 14 Fluorescence. *Biochemistry* 45, 2752–2760.
- 33
- 34
- 35 15 (26) Wanker, E. E., Scherzinger, E., Heiser, V., Sittler, A., Eickhoff, H., and Lehrach, H. (1999)
- 36
- 37 16 Membrane filter assay for detection of amyloid-like polyglutamine-containing protein
- 38
- 39 17 aggregates. *Meth. Enzymol.* 309, 375–386.
- 40
- 41
- 42 18 (27) Romão, L. F., Sousa, V. de O., Neto, V. M., and Gomes, F. C. A. (2008) Glutamate
- 43
- 44 19 activates GFAP gene promoter from cultured astrocytes through TGF-beta1 pathways. *J.*
- 45
- 46 20 *Neurochem.* 106, 746–756.
- 47
- 48
- 49 21 (28) Shugar, D. (1952) The measurement of lysozyme activity and the ultra-violet inactivation of
- 50
- 51 22 lysozyme. *Biochim Biophys Acta* 8, 302–309.
- 52
- 53
- 54 23 (25) Rodrigues, T. M., Jerónimo-Santos, A., Outeiro, T. F., Sebastião, A. M., and Diógenes, M.
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3 1 J. (2014) Challenges and promises in the development of neurotrophic factor-based therapies for
4
5 2 Parkinson's disease. *Drugs Aging* 31, 239–261.
6
7
8 3 (26) St Martin, J. L., Klucken, J., Outeiro, T. F., Nguyen, P., Keller-McGandy, C., Cantuti-
9
10 4 Castelvetti, I., Grammatopoulos, T. N., Standaert, D. G., Hyman, B. T., and McLean, P. J.
11
12 5 (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by
13
14 6 targeted over-expression of alpha-synuclein in mouse substantia nigra. *J. Neurochem.* 100,
15
16 7 1449–1457.
17
18
19
20 8 (27) Dutta, P., Ray, N., Roy, S., Dasgupta, A. K., Bouloussa, O., and Sarkar, A. (2011) Covalent
21
22 9 immobilization of active lysozyme on Si/glass surface using alkoxy Fischer carbene complex on
23
24 10 SAM. *Org. Biomol. Chem.* 9, 5123–5128.
25
26
27
28 11 (28) Bulawa, C. E., Connelly, S., Devit, M., Wang, L., Weigel, C., Fleming, J. A., Packman, J.,
29
30 12 Powers, E. T., Wiseman, R. L., Foss, T. R., Wilson, I. A., Kelly, J. W., and Labaudiniere, R.
31
32 13 (2012) Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid
33
34 14 cascade. *Proc Natl Acad Sci U S A.* 109, 9629–9634.
35
36
37
38 15
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **1 FIGURE CAPTIONS**
4

5
6 **2**
7
8 **3 Figure 1.** Catalytic oxidation of free amines from lysines into imines by *o*-iminoquinone (IQ).
9

10
11
12 **5 Figure 2.** Effect of IQ on aggregation of syn. (A) Primary sequence of syn. (B) A kinetic
13
14
15 **6** experiment of syn (70 μ M) aggregation, monitored by ThT fluorescence, was performed in the
16
17 **7** absence or in the presence of EGCG or IQ. After 60 h aggregation, the samples were: (C)
18
19 **8** fractionated by centrifugation and resolved by SDS-PAGE, (D) separated using a filter
20
21 **9** retardation assay and the membrane was stained with Ponceau, and (E) analyzed by Circular
22
23
24 **10** dichroism. (F) A monomeric solution of syn (70 μ M) was incubated in the absence or presence
25
26 **11** of 5% seeds. The seeds were produced by sonication of final product of panel B.
27
28
29
30
31

32
33 **13 Figure 3.** IQ acts upon syn aggregation through Lys modification and methionine oxidation. (A)
34
35 **14** Syn monomers (70 μ M) were incubated in the absence or presence of IQ (350 μ M) and Lys (50
36
37 **15** mM). ThT fluorescence was monitored over time. After aggregation, the morphology of the
38
39 **16** samples was analyzed by TEM (B, C and D). After 60 h incubation, the samples were analyzed
40
41 **17** by filter retardation assay (E) and mass spectrometry (F, G, H and I).
42
43
44
45
46
47

48 **19 Figure 4.** IQ remodels mature amyloid fibrils of syn. (A) Mature fibrils of syn (15 μ M) were
49
50 **20** incubated in the absence or in the presence of IQ (300 μ M) or EGCG (300 μ M) for 0 or 24 h and
51
52 **21** the ThT fluorescence was measured. (B) A kinetic analysis by filter retardation assay of aliquots
53
54
55 **22** of the samples described in panel A. TEM images of samples described in panel A after 24 h
56
57
58
59
60

1
2
3 1 incubation (C, D and E). (F) Dot blot using the LOC antibody that recognizes a generic amyloid
4
5 2 epitope. Mature syn fibrils were incubated in the absence or in the presence of IQ or EGCG for
6
7 3 24 h then spotted onto nitrocellulose membrane and then probed with LOC or syn antibody. (G)
8
9 4 A monomeric solution of syn (70 μM) was incubated in the absence or presence of 5% seeds.
10
11 5 The seeds were produced by sonication of final product of panel A after 24 h incubation.
12
13
14
15
16
17
18

19 **Figure 5.** The amyloid remodeling activity of IQ requires free amines. (A) Syn mature amyloid
20
21 8 fibrils were incubated in the presence of pyridoxal 5'-phosphate (VitB6) or acetic aldehyde (AA)
22
23 9 in order to block free amines. Chemically modified fibrils (15 μM) were incubated in the absence
24
25 10 or presence of IQ (300 μM) for 24 h and aggregation assessed using the FR assay stained with
26
27 11 Ponceau. Non-modified fibrils were used as control. (B and C) Mature fibrils of syn (15 μM)
28
29 12 were incubated alone, in the presence of IQ (300 μM), or in the presence of IQ (300 μM) and lys
30
31 13 (50 mM) for 24 h and aggregation was assessed using (B) the FR assay stained with Ponceau or
32
33 14 (C) ThT fluorescence.
34
35
36
37
38
39
40

41 **Figure 6.** IQ remodels mature amyloid fibrils of $\text{A}\beta_{1-40}$. Mature fibrils of $\text{A}\beta_{1-40}$ (A) (15 μM)
42
43 17 were incubated in the absence or in the presence of IQ (300 μM) or EGCG (300 μM) for 24 h
44
45 18 and remodeling was assessed using (B) the filter retardation assay or (C) ThT fluorescence.
46
47
48
49
50
51

52 **Figure 7.** The amyloid remodeling activity of IQ differs from EGCG. (A) $\text{IAPP}_{\text{Ac}8-24}$ mature
53
54 21 amyloid fibrils (15 μM) were incubated in the absence or presence of IQ (300 μM) or EGCG
55
56
57
58
59
60


1
2
3 1 (300 μM) for 24 h. An aliquot of these samples was boiled or not in 2% SDS and then applied to
4
5 2 FR membrane and stained with Ponceau (B) or ThT fluorescence was measured (C).
6
7
8
9 3

10
11 4 **Figure 8.** Toxicity of IQ and EGCG in murine dopaminergic cells. (A) Primary dopaminergic
12
13 5 neurons characterized by the presence of tyrosine hydroxylase and microtubule-associated
14
15 6 protein 2 (MAP2) were incubated with 100 μM zinc and different concentrations of IQ or EGCG
16
17 7 and after 24 h the viability was measured by MTT assay (B).
18
19
20
21
22 8

23
24
25 9 **Figure 9.** IQ blocks the aggregation of syn without affecting the enzymatic activity of lysozyme.
26
27 10 (A) A kinetic experiment of syn (70 μM) aggregation, monitored by ThT fluorescence, was
28
29 11 performed in the absence or in the presence of 700 μM IQ (1:10). For the competition assay, syn
30
31 12 (70 μM) was incubated in the presence of 52 μM chicken egg albumin or 175 μM egg-white
32
33 13 lysozyme. After 40 h aggregation, the samples were: (B) fractionated by centrifugation and
34
35 14 resolved by SDS-PAGE or (C and D) incubated in the presence of *Micrococcus luteus* to test for
36
37 15 the antimicrobial activity of lysozyme. After 1 h incubation, the *Micrococcus luteus* were stained
38
39 16 with ethidium homodimer and analyzed by fluorescence microscopy. Bacteria stained red (C)
40
41
42
43 17 were considered dead bacteria (D).
44
45
46
47 18
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Fig 1

7 Fig 1



2

3


1 Fig 2

7 Fig 2


A

MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLVY GSKTKEGVVH GVATVAEKTK EQVTNVGGAV
 VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEP EA


B




C




D



E



F




2

3

1 Fig 3


Fig 3



2

1 Fig 4


2 Fig 4



2

3



1 Fig 5

2
3
4
5
6 Fig 5

2

3



1 Fig 6

2
3
4
5
6 Fig 6
7
8
910
11
12 A $A\beta_{1-40}$ DAEFRHDSGYEVHHQ**KL**VFFAE
13 DVGSN**K**GAIIGLMVGGVV
14

2

3


1 Fig 7

2
3
4
5
6 Fig 7
7
8
910
11 A IAPP_{Ac8-24}ATQRLANFLVHSSNNFG

2

3

1 Fig 8





2
3
4
5
6 Fig 8

2

3


1 Fig 9

Fig 9

**B****C****D**

2

1 Table of Contents (TOC)



2

3